• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-200c缺失上调CYP1B1并赋予肾细胞癌多西他赛耐药性。

Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.

作者信息

Chang Inik, Mitsui Yozo, Fukuhara Shinichiro, Gill Ankurpreet, Wong Darryn K, Yamamura Soichiro, Shahryari Varahram, Tabatabai Z Laura, Dahiya Rajvir, Shin Dong Min, Tanaka Yuichiro

机构信息

Department of Surgery and Division of Urology, Veterans Affairs Medical Center, San Francisco, California, United States of America.

Department of Oral Biology, Yonsei University College of Dentistry, Seoul, South Korea.

出版信息

Oncotarget. 2015 Apr 10;6(10):7774-87. doi: 10.18632/oncotarget.3484.

DOI:10.18632/oncotarget.3484
PMID:25860934
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4480715/
Abstract

Despite high protein expression and enzymatic activity of cytochrome P450 1B1 (CYP1B1) in renal cell cancer (RCC), its functional significance has not been elucidated. Here we explored the functional role and regulatory mechanism of CYP1B1 in RCC. Reduction of CYP1B1 levels fail to prevent in vitro tumorigenicity such as proliferation, apoptosis, and cell cycle progression of RCC cells. Moreover, the expression levels are not associated with tumor type, stage, Fuhrman grade and 5-year survival probability after surgery. Instead, alteration of CYP1B1 expression regulates the chemosensitivity of RCC cells to docetaxel suggesting its critical contribution to the chemoresistance. Additionally, miR-200c, which is significantly down-regulated in RCC regulates CYP1B1 expression and activity. An inverse association was also observed between the expression levels of miR-200c and CYP1B1 protein in RCC tissues. Finally, alteration of miR-200c levels affects the chemosensitivity of RCC cells. Restoration of docetaxel resistance by exogenous expression of CYP1B1 in miR-200c-over-expressing cells indicates that CYP1B1 is a functional target of miR-200c. These results suggest that CYP1B1 up-regulation mediated by low miR-200c is one of the mechanisms underlying resistance of RCC cells to docetaxel. Therefore, expression of CYP1B1 and miR-200c in RCC may be useful as a prediction for docetaxel response.

摘要

尽管细胞色素P450 1B1(CYP1B1)在肾细胞癌(RCC)中具有高蛋白质表达和酶活性,但其功能意义尚未阐明。在此,我们探讨了CYP1B1在RCC中的功能作用和调控机制。降低CYP1B1水平并不能阻止RCC细胞的体外致瘤性,如增殖、凋亡和细胞周期进程。此外,其表达水平与肿瘤类型、分期、Fuhrman分级及术后5年生存概率无关。相反,CYP1B1表达的改变调节了RCC细胞对多西他赛的化学敏感性,表明其对化疗耐药性有重要作用。此外,在RCC中显著下调的miR-200c调节CYP1B1的表达和活性。在RCC组织中还观察到miR-200c和CYP1B1蛋白表达水平呈负相关。最后,miR-200c水平的改变影响RCC细胞的化学敏感性。在过表达miR-200c的细胞中外源表达CYP1B1恢复多西他赛耐药性,表明CYP1B1是miR-200c的功能靶点。这些结果表明,低miR-200c介导的CYP1B1上调是RCC细胞对多西他赛耐药的潜在机制之一。因此,RCC中CYP1B1和miR-200c的表达可能有助于预测多西他赛的反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/d62c86a6a5cd/oncotarget-06-7774-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/b6b0bb3ee56f/oncotarget-06-7774-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/a9ca61cc2ef5/oncotarget-06-7774-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/53b9db4db59a/oncotarget-06-7774-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/5433eadc59aa/oncotarget-06-7774-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/f91a6f7f139b/oncotarget-06-7774-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/d62c86a6a5cd/oncotarget-06-7774-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/b6b0bb3ee56f/oncotarget-06-7774-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/a9ca61cc2ef5/oncotarget-06-7774-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/53b9db4db59a/oncotarget-06-7774-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/5433eadc59aa/oncotarget-06-7774-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/f91a6f7f139b/oncotarget-06-7774-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7add/4480715/d62c86a6a5cd/oncotarget-06-7774-g006.jpg

相似文献

1
Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma.miR-200c缺失上调CYP1B1并赋予肾细胞癌多西他赛耐药性。
Oncotarget. 2015 Apr 10;6(10):7774-87. doi: 10.18632/oncotarget.3484.
2
CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.细胞色素P450 1B1(CYP1B1)通过改变肾细胞癌中细胞分裂周期蛋白20(CDC20)和死亡相关蛋白激酶1(DAPK1)基因的表达促进肿瘤发生。
BMC Cancer. 2015 Dec 1;15:942. doi: 10.1186/s12885-015-1951-0.
3
microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.miRNA-200c 调控人肾透明细胞癌转移中的上皮间质转化。
Oncol Rep. 2013 Aug;30(2):643-50. doi: 10.3892/or.2013.2530. Epub 2013 Jun 7.
4
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.微小RNA-30a介导的自噬抑制使肾癌细胞对索拉非尼敏感。
Biochem Biophys Res Commun. 2015 Apr 3;459(2):234-239. doi: 10.1016/j.bbrc.2015.02.084. Epub 2015 Feb 21.
5
MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene.MicroRNA-451 通过靶向 ATF-2 基因调节肾细胞癌的化疗耐药性。
Exp Biol Med (Maywood). 2017 Jun;242(12):1299-1305. doi: 10.1177/1535370217701625. Epub 2017 Apr 21.
6
miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma.微小RNA-200c靶向细胞周期蛋白依赖性激酶2并抑制肾细胞癌的肿瘤发生。
Mol Cancer Res. 2015 Dec;13(12):1567-77. doi: 10.1158/1541-7786.MCR-15-0128. Epub 2015 Aug 6.
7
miR-1293 Suppresses Tumor Malignancy by Targeting Hydrocyanic Oxidase 2: Therapeutic Potential of a miR-1293/Hydrocyanic Oxidase 2 Axis in Renal Cell Carcinoma.miR-1293 通过靶向氰酸酶 2 抑制肿瘤恶性转化:miR-1293/氰酸酶 2 轴在肾细胞癌中的治疗潜力。
Cancer Biother Radiopharm. 2020 Jun;35(5):377-386. doi: 10.1089/cbr.2019.2957. Epub 2020 Jan 22.
8
MicroRNA-106b functions as an oncogene in renal cell carcinoma by affecting cell proliferation, migration and apoptosis.微小RNA-106b通过影响细胞增殖、迁移和凋亡在肾细胞癌中发挥癌基因作用。
Mol Med Rep. 2016 Feb;13(2):1420-6. doi: 10.3892/mmr.2015.4656. Epub 2015 Dec 8.
9
Methylation-mediated miR-214 regulates proliferation and drug sensitivity of renal cell carcinoma cells through targeting LIVIN.甲基化介导的 miR-214 通过靶向 LIVIN 调节肾细胞癌细胞的增殖和药物敏感性。
J Cell Mol Med. 2020 Jun;24(11):6410-6425. doi: 10.1111/jcmm.15287. Epub 2020 May 12.
10
miR-27a promotes cell proliferation and metastasis in renal cell carcinoma.微小RNA-27a促进肾细胞癌的细胞增殖和转移。
Int J Clin Exp Pathol. 2015 Feb 1;8(2):2259-66. eCollection 2015.

引用本文的文献

1
Proanthocyanidins inhibit CYP1B1 through mixed-type kinetics and stable binding in molecular dynamics simulations.原花青素通过混合型动力学抑制CYP1B1,并在分子动力学模拟中具有稳定结合。
Sci Rep. 2025 Aug 29;15(1):31877. doi: 10.1038/s41598-025-12781-2.
2
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.探索个体药物代谢特征的新方法,推进精准医学发展。
Drug Metab Dispos. 2023 Oct;51(10):1238-1253. doi: 10.1124/dmd.122.001066. Epub 2023 Jul 7.
3
CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer.

本文引用的文献

1
miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.miR-200c 通过降低 TrkB 和 Bmi1 的表达使乳腺癌细胞对阿霉素治疗更敏感。
PLoS One. 2012;7(11):e50469. doi: 10.1371/journal.pone.0050469. Epub 2012 Nov 29.
2
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.恢复卵巢癌细胞中的 miR-200c 可降低肿瘤负担并增加对紫杉醇的敏感性。
Mol Cancer Ther. 2012 Dec;11(12):2556-65. doi: 10.1158/1535-7163.MCT-12-0463. Epub 2012 Oct 16.
3
A miR-200b/200c/429-binding site polymorphism in the 3' untranslated region of the AP-2α gene is associated with cisplatin resistance.
CYP1B1 通过降解 ACSL4 抑制结直肠癌细胞铁死亡并诱导抗 PD-1 耐药性。
Cell Death Dis. 2023 Apr 14;14(4):271. doi: 10.1038/s41419-023-05803-2.
4
A four-microRNA panel in serum may serve as potential biomarker for renal cell carcinoma diagnosis.血清中的一个包含四种微小RNA的组合可能作为肾细胞癌诊断的潜在生物标志物。
Front Oncol. 2023 Jan 16;12:1076303. doi: 10.3389/fonc.2022.1076303. eCollection 2022.
5
Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.遗传多态性在药物代谢酶介导的毒性和抗癌药物药代动力学耐药中的作用:药物基因组学方面的综述。
Clin Pharmacokinet. 2022 Nov;61(11):1495-1517. doi: 10.1007/s40262-022-01174-7. Epub 2022 Sep 30.
6
Ru(II) photocages enable precise control over enzyme activity with red light.Ru(II) 光笼使我们能够用红光精确控制酶的活性。
Nat Commun. 2022 Jun 25;13(1):3636. doi: 10.1038/s41467-022-31269-5.
7
MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.微小RNA与癌症耐药性:两千余字探寻其作用
Cancer Drug Resist. 2019 Sep 19;2(3):618-633. doi: 10.20517/cdr.2019.55. eCollection 2019.
8
Development of 2-arylbenzo[]quinolone analogs as selective CYP1B1 inhibitors.2-芳基苯并[]喹诺酮类似物作为选择性CYP1B1抑制剂的研发。
RSC Adv. 2018 Apr 20;8(27):15009-15020. doi: 10.1039/c8ra00465j. eCollection 2018 Apr 18.
9
The Roles of microRNAs in Cancer Multidrug Resistance.微小RNA在癌症多药耐药中的作用
Cancers (Basel). 2022 Feb 21;14(4):1090. doi: 10.3390/cancers14041090.
10
Quaking I-5 protein inhibits invasion and migration of kidney renal clear cell carcinoma via inhibiting epithelial-mesenchymal transition suppression through the regulation of microRNA 200c.震颤蛋白I-5通过调控微小RNA 200c抑制上皮-间质转化,从而抑制肾透明细胞癌的侵袭和迁移。
Transl Androl Urol. 2021 Oct;10(10):3800-3814. doi: 10.21037/tau-21-833.
AP-2α 基因 3'非翻译区 miR-200b/200c/429 结合位点多态性与顺铂耐药相关。
PLoS One. 2011;6(12):e29043. doi: 10.1371/journal.pone.0029043. Epub 2011 Dec 14.
4
miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation.miRNA 谱分析在透明细胞肾细胞癌中的应用:生物标志物的发现以及 miRNA 失调的潜在调控和后果的鉴定。
J Urol. 2011 Sep;186(3):1077-83. doi: 10.1016/j.juro.2011.04.110. Epub 2011 Jul 23.
5
Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.miR-200c 的过表达通过激活 Akt 信号通路诱导食管癌的化疗耐药。
Clin Cancer Res. 2011 May 1;17(9):3029-38. doi: 10.1158/1078-0432.CCR-10-2532. Epub 2011 Jan 19.
6
Estrogen and cytochrome P450 1B1 contribute to both early- and late-stage head and neck carcinogenesis.雌激素和细胞色素 P450 1B1 促进头颈部癌症的早期和晚期发生。
Cancer Prev Res (Phila). 2011 Jan;4(1):107-15. doi: 10.1158/1940-6207.CAPR-10-0133. Epub 2012 Dec 31.
7
The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.miR-200 家族控制着微管相关蛋白 III 的表达,与卵巢癌患者对紫杉醇类药物治疗的反应和无进展生存期相关。
Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.
8
Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models.细胞色素 P450 1B1 基因多态性作为抗癌药物活性的预测因子:体外模型研究。
Mol Cancer Ther. 2010 Dec;9(12):3315-21. doi: 10.1158/1535-7163.MCT-10-0673. Epub 2010 Oct 1.
9
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.细胞色素 450 1B1(CYP1B1)多态性与去势抵抗性前列腺癌(CRPC)患者对多西他赛的反应相关。
BMC Cancer. 2010 Sep 27;10:511. doi: 10.1186/1471-2407-10-511.
10
Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.miR-200c 表达缺失导致非小细胞肺癌中侵袭性、耐药表型的产生。
Mol Cancer Res. 2010 Sep;8(9):1207-16. doi: 10.1158/1541-7786.MCR-10-0052. Epub 2010 Aug 9.